SCHEMBL197785

SCHEMBL197785

CCOC(=O)COc1ccc(OCc2ccccc2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 3/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
MAPT P10636 1/20 0.51
FFAR1 O14842 1/20 0.51
P4HTM Q9NXG6 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
NR1H4 Q96RI1 1/20 0.49
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ACACB O00763 2/20 0.47
ACACA Q13085 1/20 0.47
NPC1 O15118 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
GAA P10253 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6187602 0.85 NR1H4 (0.64) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL8625075 0.82 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL20406241 0.82 NR1H4 (0.51) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL198509 0.79 PPARA (0.50) ALDH1A1FFAR1P4HTMNR1H4LMNA
SCHEMBL13720748 0.79 PPARA (0.62) ALDH1A1KDM4EHPGDSMN1; SMN2NR1H4
SCHEMBL30697582 0.78 PRMT5 (0.60) ALDH1A1FFAR1P4HTMNR1H4LMNA
SCHEMBL434950 0.78 MAPT (0.47) ALDH1A1HPGDMAPTFFAR1SMN1; SMN2
SCHEMBL7009532 0.76 KMT2A (0.58) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL2438238 0.76 GAA (0.58) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL5737702 0.76 NR1H4 (0.51) ALDH1A1KDM4EMAPTFFAR1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321282-B1 NEW BENZIMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2013-03-27 EP disclosed
US-8088930-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
EP-2321282-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010028981-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-18 WO disclosed
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES CYP3A7, ECI1, CYP2B6 ALDH1A1 39/4885KDM4E 1959/4885HPGD 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.